NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

Well it seems all but impossible that we would have unimpressive results based on what we saw with the still blinded data.
https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/

Median OS From Surgery__________Survival 1 yr__Survival 2 yrs__Survival 3 yrs
2018 methylated 35.1 months________94.6%______66.6%______49.1%
2018 unmethylated 19.8 months______86.4%______32.6%______14.3%

With that said with > 90% of the patients receiving DCVAX at some point in the trial there is a risk that even the crossover patients see significant benefit so we don't see a big different between the patients that received DCVAX day 1 and those that got it later after progression. The argument that that won't be the case is that the GBM tumor cells will continue to mutate and the vaccine produced from exposure to the original resected tumor may not be as effective since the mutated cell with likely have a different antigen profile. That makes sense to me.

The other concern is that we already see federal agencies (e.g. The CDC with President Trump this week messing with the covid vaccine approval guide lines) may not play it fair and straight. That is a greater concern to me than DCVAX not proving far more effective than SOC for GBM. Big Pharma has deep pockets and deep pockets can influence and corrupt people in decision making positions. Lets hope and pray that is not the case if this really such an effective treatment that can save and restore many patient's lives. GLTU